Your browser doesn't support javascript.
loading
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for clinical microbiology in 2014: General view of the pathogens' antibacterial susceptibility.
Yanagihara, Katsunori; Matsumoto, Tetsuya; Aoki, Nobuki; Sato, Junko; Wakamura, Tomotaro; Kiyota, Hiroshi; Tateda, Kazuhiro; Hanaki, Hideaki; Ohsaki, Yoshinobu; Fujiuchi, Satoru; Takahashi, Manabu; Akiba, Yuji; Masunaga, Shingo; Takeuchi, Kenichi; Takeda, Hiroaki; Miki, Makoto; Kumagai, Toshio; Takahashi, Hiroshi; Utagawa, Mutsuko; Nishiya, Hajime; Kawakami, Sayoko; Ishigaki, Shinobu; Kobayasi, Nobuyuki; Takasaki, Jin; Mezaki, Kazuhisa; Iwata, Satoshi; Katouno, Yasuhiro; Inose, Rika; Niki, Yoshihito; Kawana, Akihiko; Fujikura, Yuji; Kudo, Makoto; Hirano, Tomo; Yamamoto, Masaki; Miyazawa, Naoki; Tsukada, Hiroki; Aso, Sakura; Yamamoto, Yoshihiro; Iinuma, Yoshitsugu; Mikamo, Hiroshige; Yamagishi, Yuka; Nakamura, Atsushi; Ohashi, Minoru; Kawabata, Atsushi; Sugaki, Yoshiko; Seki, Masafumi; Hamaguchi, Shigeto; Toyokawa, Masahiro; Kakeya, Hiroshi; Fujikawa, Yasunori.
Afiliação
  • Yanagihara K; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan; Nagasaki University School of Medicine, Nagasaki, Japan. Electronic address: k-yanagi@nagasaki-u.ac.j
  • Matsumoto T; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Aoki N; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Sato J; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Wakamura T; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Kiyota H; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Tateda K; The Surveillance Committee of Japanese Society of Chemotherapy (JSC), The Japanese Association for Infectious Diseases (JAID) and the Japanese Society for Clinical Microbiology (JSCM), Tokyo, Japan.
  • Hanaki H; The Kitasato Institute, Tokyo, Japan.
  • Ohsaki Y; Asahikawa Medical University, Hokkaido, Japan.
  • Fujiuchi S; National Hospital Organization Asahikawa Medical Center, Hokkaido, Japan.
  • Takahashi M; National Hospital Organization Asahikawa Medical Center, Hokkaido, Japan.
  • Akiba Y; Asahikawa Kosei Hospital, Hokkaido, Japan.
  • Masunaga S; Asahikawa Kosei Hospital, Hokkaido, Japan.
  • Takeuchi K; Iwate Prefectural Central Hospital, Iwate, Japan.
  • Takeda H; Saiseikai Yamagata Saisei Hospital, Yamagata, Japan.
  • Miki M; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
  • Kumagai T; Japanese Red Cross Sendai Hospital, Miyagi, Japan.
  • Takahashi H; Saka General Hospital, Miyagi, Japan.
  • Utagawa M; Saka General Hospital, Miyagi, Japan.
  • Nishiya H; Teikyo University Hospital, Tokyo, Japan.
  • Kawakami S; Teikyo University Hospital, Tokyo, Japan.
  • Ishigaki S; Teikyo University Hospital, Tokyo, Japan.
  • Kobayasi N; National Center for Global Health and Medicine, Tokyo, Japan.
  • Takasaki J; National Center for Global Health and Medicine, Tokyo, Japan.
  • Mezaki K; National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwata S; Keio University Hospital, Tokyo, Japan.
  • Katouno Y; Keio University Hospital, Tokyo, Japan.
  • Inose R; Keio University Hospital, Tokyo, Japan.
  • Niki Y; Showa University School of Medicine, Tokyo, Japan.
  • Kawana A; National Defense Medical College Hospital, Saitama, Japan.
  • Fujikura Y; National Defense Medical College Hospital, Saitama, Japan.
  • Kudo M; Yokohama City University Hospital, Kanagawa, Japan.
  • Hirano T; Yokohama City University Hospital, Kanagawa, Japan.
  • Yamamoto M; Yokohama City University Hospital, Kanagawa, Japan.
  • Miyazawa N; Saiseikai Yokohamashi Nanbu Hospital, Kanagawa, Japan.
  • Tsukada H; Niigata City General Hospital, Niigata, Japan.
  • Aso S; Niigata City General Hospital, Niigata, Japan.
  • Yamamoto Y; Toyama University Hospital, Toyama, Japan.
  • Iinuma Y; Kanazawa Medical University, Ishikawa, Japan.
  • Mikamo H; Aichi Medical University Hospital, Aichi, Japan.
  • Yamagishi Y; Aichi Medical University Hospital, Aichi, Japan.
  • Nakamura A; Nagoya City University Hospital, Aichi, Japan.
  • Ohashi M; Nagoya City University Hospital, Aichi, Japan.
  • Kawabata A; Toyota Memorial Hospital, Aichi, Japan.
  • Sugaki Y; Toyota Memorial Hospital, Aichi, Japan.
  • Seki M; Osaka University Hospital, Osaka, Japan.
  • Hamaguchi S; Osaka University Hospital, Osaka, Japan.
  • Toyokawa M; Osaka University Hospital, Osaka, Japan.
  • Kakeya H; Osaka City University Hospital, Osaka, Japan.
  • Fujikawa Y; Osaka City General Hospital, Osaka, Japan.
J Infect Chemother ; 25(9): 657-668, 2019 Sep.
Article em En | MEDLINE | ID: mdl-31196772
ABSTRACT
The nationwide surveillance on antimicrobial susceptibility of bacterial respiratory pathogens from the patients in Japan was conducted by Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2014. The isolates were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections during the period between January 2014 and April 2015 by three societies. Antimicrobial susceptibility testing was conducted at the central reference laboratory according to the method recommended by Clinical Laboratory Standards Institute. Susceptibility testing was evaluated in 1534 strains (335 Staphylococcus aureus, 264 Streptococcus pneumoniae, 29 Streptococcus pyogenes, 281 Haemophilus influenzae, 164 Moraxella catarrhalis, 207 Klebsiella pneumoniae, and 254 Pseudomonas aeruginosa). Ratio of methicillin-resistant S. aureus was 43.6%, and those of penicillin-susceptible S. pneumoniae was 100%. Among H. influenzae, 8.2% of them were found to be ß-lactamase-producing ampicillin-resistant strains, and 49.1% to be ß-lactamase-non-producing ampicillin-resistant strains. Extended spectrum ß-lactamase-producing K. pneumoniae and multi-drug resistant P. aeruginosa with metallo ß-lactamase were 9.2% and 0.4%, respectively.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Farmacorresistência Bacteriana / Monitoramento Epidemiológico / Antibacterianos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Farmacorresistência Bacteriana / Monitoramento Epidemiológico / Antibacterianos Idioma: En Ano de publicação: 2019 Tipo de documento: Article